MEK inhibitor nears approval
REGISTER
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

MEK inhibitor nears approval

› Forums › General Melanoma Community › MEK inhibitor nears approval

  • Post
Viewing 5 reply threads
  • Replies
      • January 11, 2013 at 3:01 am
      NYKaren
      Participant
      I wonder what “could be close to reaching the market” really means. Anyone hear anything more specific?
      • January 11, 2013 at 3:01 am
      NYKaren
      Participant
      I wonder what “could be close to reaching the market” really means. Anyone hear anything more specific?
        • January 12, 2013 at 3:09 pm
        lou2
        Participant

        Probably only the FDA knows the answer to your question.  It apparently is in the process of approval, however long that might take.

        Here is a link that gives info on the process:

        http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm054420.htm

         

        And here is another report on the application, which gives contact info for the maker of the drug:

        August 07, 2012

        NDAs Submitted for Dabrafenib and Trametinib for Unresectable or Metastatic Melanoma

        GlaxoSmithKline announced that it has submitted New Drug Applications (NDAs) for dabrafenib and trametinib to the FDA, seeking approval for the treatment of patients with unresectable or metastatic melanoma with BRAF V600 mutation as detected by an FDA-approved test.

        GlaxoSmithKline entered a collaboration with bioMérieux in 2010 to develop a molecular theranostic test to detect BRAF V600 (V600E and V600K) gene mutations found in several cancers, including melanoma. bioMérieux has filed for FDA Pre-Market Approval of the test and it is currently being utilized in the Phase 3 trametinib-dabrafenib combination program to identify appropriate patients.

        Dabrafenib is a BRAF inhibitor. Trametinib is an MEK inhibitor.

        For more information call (888) 825 5249 or visit http://www.gsk.com.

        • January 12, 2013 at 3:18 pm
        lou2
        Participant

        I found this on the GSK website, which was interesting because of the opthomologic and cardiac problems reported from the clinical trial on the drug.  Wondering if this info will be available to patients or only to researchers, and whether it applies only in the UK, since it was a British medical journal decision about transparency?

         

        http://www.gsk.com/media/press-releases/2012/gsk-responds-bmj-commitment-clinical-trial-data-transparency.html

        • January 12, 2013 at 10:42 pm
        NYKaren
        Participant
        Interesting, Lou. My my onc says the combo is loaded w/side effects, but he wasn’t specific.
        • January 12, 2013 at 10:42 pm
        NYKaren
        Participant
        Interesting, Lou. My my onc says the combo is loaded w/side effects, but he wasn’t specific.
        • January 12, 2013 at 10:42 pm
        NYKaren
        Participant
        Interesting, Lou. My my onc says the combo is loaded w/side effects, but he wasn’t specific.
        • January 12, 2013 at 3:18 pm
        lou2
        Participant

        I found this on the GSK website, which was interesting because of the opthomologic and cardiac problems reported from the clinical trial on the drug.  Wondering if this info will be available to patients or only to researchers, and whether it applies only in the UK, since it was a British medical journal decision about transparency?

         

        http://www.gsk.com/media/press-releases/2012/gsk-responds-bmj-commitment-clinical-trial-data-transparency.html

        • January 12, 2013 at 3:18 pm
        lou2
        Participant

        I found this on the GSK website, which was interesting because of the opthomologic and cardiac problems reported from the clinical trial on the drug.  Wondering if this info will be available to patients or only to researchers, and whether it applies only in the UK, since it was a British medical journal decision about transparency?

         

        http://www.gsk.com/media/press-releases/2012/gsk-responds-bmj-commitment-clinical-trial-data-transparency.html

        • January 12, 2013 at 3:09 pm
        lou2
        Participant

        Probably only the FDA knows the answer to your question.  It apparently is in the process of approval, however long that might take.

        Here is a link that gives info on the process:

        http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm054420.htm

         

        And here is another report on the application, which gives contact info for the maker of the drug:

        August 07, 2012

        NDAs Submitted for Dabrafenib and Trametinib for Unresectable or Metastatic Melanoma

        GlaxoSmithKline announced that it has submitted New Drug Applications (NDAs) for dabrafenib and trametinib to the FDA, seeking approval for the treatment of patients with unresectable or metastatic melanoma with BRAF V600 mutation as detected by an FDA-approved test.

        GlaxoSmithKline entered a collaboration with bioMérieux in 2010 to develop a molecular theranostic test to detect BRAF V600 (V600E and V600K) gene mutations found in several cancers, including melanoma. bioMérieux has filed for FDA Pre-Market Approval of the test and it is currently being utilized in the Phase 3 trametinib-dabrafenib combination program to identify appropriate patients.

        Dabrafenib is a BRAF inhibitor. Trametinib is an MEK inhibitor.

        For more information call (888) 825 5249 or visit http://www.gsk.com.

        • January 12, 2013 at 3:09 pm
        lou2
        Participant

        Probably only the FDA knows the answer to your question.  It apparently is in the process of approval, however long that might take.

        Here is a link that gives info on the process:

        http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm054420.htm

         

        And here is another report on the application, which gives contact info for the maker of the drug:

        August 07, 2012

        NDAs Submitted for Dabrafenib and Trametinib for Unresectable or Metastatic Melanoma

        GlaxoSmithKline announced that it has submitted New Drug Applications (NDAs) for dabrafenib and trametinib to the FDA, seeking approval for the treatment of patients with unresectable or metastatic melanoma with BRAF V600 mutation as detected by an FDA-approved test.

        GlaxoSmithKline entered a collaboration with bioMérieux in 2010 to develop a molecular theranostic test to detect BRAF V600 (V600E and V600K) gene mutations found in several cancers, including melanoma. bioMérieux has filed for FDA Pre-Market Approval of the test and it is currently being utilized in the Phase 3 trametinib-dabrafenib combination program to identify appropriate patients.

        Dabrafenib is a BRAF inhibitor. Trametinib is an MEK inhibitor.

        For more information call (888) 825 5249 or visit http://www.gsk.com.

        • January 15, 2013 at 11:46 pm
        john partrick michael murphy
        Participant
        I have been taking the MEK inhibitor, with the BRAF inhibitor for over two years, and i would not say “it is loaded with side affects.” I say it is wonderful, with a few mild side affects, and many of my cohorts feel the same way.
        • January 15, 2013 at 11:46 pm
        john partrick michael murphy
        Participant
        I have been taking the MEK inhibitor, with the BRAF inhibitor for over two years, and i would not say “it is loaded with side affects.” I say it is wonderful, with a few mild side affects, and many of my cohorts feel the same way.
        • January 17, 2013 at 1:08 am
        NYKaren
        Participant
        Dear JPMM,
        Thanks for sharing that. Funny, on my last visit to Sloan, both onc & his fellow were saying lots of side-effects for the combo. Go figure.
        I wish you ever-lasting response and few to no side effects.
        Karen
        • January 17, 2013 at 1:08 am
        NYKaren
        Participant
        Dear JPMM,
        Thanks for sharing that. Funny, on my last visit to Sloan, both onc & his fellow were saying lots of side-effects for the combo. Go figure.
        I wish you ever-lasting response and few to no side effects.
        Karen
        • January 17, 2013 at 1:08 am
        NYKaren
        Participant
        Dear JPMM,
        Thanks for sharing that. Funny, on my last visit to Sloan, both onc & his fellow were saying lots of side-effects for the combo. Go figure.
        I wish you ever-lasting response and few to no side effects.
        Karen
        • January 15, 2013 at 11:46 pm
        john partrick michael murphy
        Participant
        I have been taking the MEK inhibitor, with the BRAF inhibitor for over two years, and i would not say “it is loaded with side affects.” I say it is wonderful, with a few mild side affects, and many of my cohorts feel the same way.
      • January 11, 2013 at 3:01 am
      NYKaren
      Participant
      I wonder what “could be close to reaching the market” really means. Anyone hear anything more specific?
      • January 13, 2013 at 1:48 am
      Wife of Carl
      Participant

      My husband has been on a clinical trial for the GSK MEK inhibitor for 2 1/2 years.  His doctor said that he got notice from GSK that it would be on the market this spring.

      Pat

      • January 13, 2013 at 1:48 am
      Wife of Carl
      Participant

      My husband has been on a clinical trial for the GSK MEK inhibitor for 2 1/2 years.  His doctor said that he got notice from GSK that it would be on the market this spring.

      Pat

        • January 13, 2013 at 2:03 am
        NYKaren
        Participant
        Hi Pat,
        Is he on the MEK inhibitor alone or in combo with the BRAF inhibitor?
        • January 13, 2013 at 2:03 am
        NYKaren
        Participant
        Hi Pat,
        Is he on the MEK inhibitor alone or in combo with the BRAF inhibitor?
        • January 13, 2013 at 6:42 pm
        Wife of Carl
        Participant

        He is on the MEK inhibitor alone.

        • January 13, 2013 at 6:42 pm
        Wife of Carl
        Participant

        He is on the MEK inhibitor alone.

        • January 13, 2013 at 6:42 pm
        Wife of Carl
        Participant

        He is on the MEK inhibitor alone.

        • January 13, 2013 at 2:03 am
        NYKaren
        Participant
        Hi Pat,
        Is he on the MEK inhibitor alone or in combo with the BRAF inhibitor?
      • January 13, 2013 at 1:48 am
      Wife of Carl
      Participant

      My husband has been on a clinical trial for the GSK MEK inhibitor for 2 1/2 years.  His doctor said that he got notice from GSK that it would be on the market this spring.

      Pat

Viewing 5 reply threads
  • You must be logged in to reply to this topic.
About the MRF Patient Forum

The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

Popular Topics